BNT3213 / BioNTech - LARVOL DELTA

A Clinical Trial to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC (clinicaltrials.gov) - P1/2 | N=140 | Not yet recruiting | Sponsor: Biotheus Inc.

Metastases • New P1/2 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

Phase I safety and preliminary efficacy of PM1009, a bispecific antibody targeting TIGIT and PVRIG, in patients with advanced solid tumors. (ASCO 2024) - P1 | "PM1009 was well-tolerated up to 1200 mg with signs of anti-tumor activity. These findings support further clinical investigation of PM1009 especially for the combination with chemotherapy or PD-1/L1-based checkpoint inhibitors. Clinical trial information: NCT05607563."

Clinical • Metastases • P1 data • Cardiovascular • Myocardial Infarction • Oncology • Solid Tumor • NECTIN2 • PVR • TIGIT

A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Biotheus Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology

A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours (clinicaltrials.gov) - P1 | N=54 | Not yet recruiting | Sponsor: Biotheus Inc.

New P1 trial • Oncology